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Abstract (250 words) 41 
 42 
Background: Clinical performance of the novel high-sensitivity cardiac troponin I (Siemens-43 
hs-cTnI-Centaur) assay is unknown. We aimed to clinically validate the Siemens-hs-cTnI-44 
Centaur assay and develop 0/1h- and 0/2h-algorithms. 45 
Methods: We enrolled patients presenting to the emergency department with symptoms 46 
suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by 47 
two independent cardiologists including all clinical information twice: first, using serial hs-48 
cTnT (Roche-Elecsys, primary analysis) and second, using hs-cTnI (Abbott-Architect, 49 
secondary analysis) measurements in addition to the clinically applied (hs)-cTn. Siemens-hs-50 
cTnI-Centaur was measured at presentation, at 1h, and 2h. Primary objective was a direct 51 
comparison of diagnostic accuracy, quantified by the area under the receiver-operating-52 
characteristic curve (AUC), of Siemens-hs-cTnI-Centaur versus the two established hs-cTn 53 
assays (Roche-hs-cTnT-Elecsys, Abbott-hs-cTnI-Architect). Secondary objectives included the 54 
development of Siemens-hs-cTnI-Centaur specific 0/1h- and 0/2h-algorithms.  55 
Results: AMI was the final diagnosis in 318/1755 (18%) patients (using Roche-hs-cTnT-56 
Elecsys for adjudication). The AUC at presentation for Siemens-hs-cTnI-Centaur was 0.94 57 
(95%CI, 0.92-0.96) and comparable to 0.95 (95%CI, 0.93-0.97) for Roche-hs-cTnT-Elecsys 58 
and 0.93 (95%CI, 0.90-0.96) for Abbott-hs-cTnI-Architect. Applying the derived Siemens-hs-59 
cTnI-Centaur 0/1h-algorithm to the validation cohort, 46% of patients were ruled-out 60 
(sensitivity 99.1% [95%CI, 95.3-100]), and 18% of patients were ruled-in (specificity 94.1% 61 
[95%CI, 91.8-95.9]). The Siemens-hs-cTnI-Centaur 0/2h-algorithm ruled-out 55% of patients 62 
(sensitivity 100% [95%CI, 94.1-100]), and ruled-in 18% of patients (specificity 96.0% [95%CI, 63 
93.1-97.9]). Findings were confirmed in the secondary analyses using serial measurements of  64 
Abbott-hs-cTnI-Architect for adjudication. 65 
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Conclusions: Diagnostic accuracy and clinical utility of the novel Siemens-hs-cTnI-Centaur 66 
assay are very high and comparable to the established hs-cTn assays.  67 
Trial Registration: ClinicalTrials.gov number, NCT00470587 68 
 69 
Abbreviations 70 
ED – Emergency department 71 
AMI – Acute myocardial infarction 72 
ECG – Electrocardiography 73 
 74 
cTn – Cardiac troponin 75 
hs-cTn – High-sensitivity cardiac troponin 76 
eGFR – Estimated glomerular filtration rate 77 
NPV – Negative predictive value 78 
CART – Classification and regression tree 79 
PPV – Positive predictive value 80 
IQR – Interquartile range 81 
 82 
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Introduction 90 
Up to 10% of all emergency department (ED) consultations are by patients with symptoms 91 
suggestive of acute myocardial infarction (AMI).(1) Rapid identification of AMI as a life-92 
threatening disorder is important for the early initiation of appropriate, evidence-based 93 
therapy.(2) Electrocardiography (ECG) and cardiac troponin (cTn) form the diagnostic 94 
cornerstones and complement clinical assessment in the early rule-out or rule-in of AMI.(2–4)  95 
The introduction of high-sensitivity cardiac troponin (hs-cTn) assays enabled reliable 96 
measurement of cTn concentrations in the reference interval,(5) and increased diagnostic 97 
accuracy for AMI at presentation.(6) Two hs-cTn assays, Roche-hs-cTnT-Elecsys  and Abbott-98 
hs-cTnI-Architect, have been extensively investigated in large diagnostic studies, including the 99 
successful derivation and validation of early 0/1h and 0/2h triage-algorithms.(3,7–20)  100 
More recently, the novel hs-cTnI-Centaur assay was developed. It constitutes only the 101 
third hs-cTn assay to become available for clinical use. Before its possible implementation into 102 
routine clinical care, its performance in patients presenting with suspected AMI must be 103 
thoroughly examined. We therefore set out to compare its diagnostic accuracy with that of the 104 
two established hs-cTn assays, and derived and validated assay-specific 0/1h- and 0/2h-105 
algorithms. 106 
107 
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Materials and Methods 108 
Study design and population  109 
Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE), is an ongoing 110 
prospective international multicenter study with 12 centers in 5 countries aiming to advance the 111 
early diagnosis of AMI (ClinicalTrials.gov registry, number 112 
NCT00470587).(6,7,9,11,12,14,15,21–23; Online Supplemental file). 113 
 114 
Adjudication of the final diagnosis 115 
Central adjudication of the final diagnosis was performed by two independent cardiologists 116 
applying the universal definition of AMI using two sets of data: first, all available medical 117 
records obtained during clinical care including cardiac imaging and second, study-specific 118 
assessments including serial hs-cTnT concentrations. In order to address the uncommon, but 119 
previously described phenomenon of discrepant results for hs-cTnT and hs-cTnI, we performed 120 
a second adjudication using serial hs-cTnI (rather than hs-cTnT) blood concentrations from 121 
study samples (Online Supplemental). 122 
 123 
Investigational hs-cTn measurements 124 
For determination of Siemens-hs-cTnI-Centaur we used blood samples collected into serum 125 
containers and for determination of Abbott-hs-cTnI-Architect and Roche-hs-cTnT-Elecsys we 126 
used blood samples collected into serum containers or lithium heparin plasma containers, 127 
respectively. Study-specific blood draws were performed immediately after informed consent 128 
had been obtained at ED presentation and additionally at 1, 2, 3, and 6h. Serial sampling was 129 
discontinued when a patient was released or transferred to the catheter laboratory for acute 130 
treatment. After centrifugation, samples were frozen at -80°C until assayed in a blinded fashion 131 
in a dedicated core laboratory. 132 
According to the manufacturer, the hs-cTnI-Centaur assay (ADVIA Centaur TNIH, Siemens 133 
Healthcare) has a population 99th percentile concentration (both sexes) of 47ng/L with a 134 
6 
 
corresponding co-efficient of variation (CV) of <5%. 99th percentiles for men and women are 135 
58ng/L and 39ng/L, respectively. Limit of blank (LoB), limit of detection (LoD), and limit of 136 
quantification (LoQ) have been determined to be 0.9ng/L, 2.2ng/L, and 2.5ng/L. The assay is a 137 
dual-capture sandwich immunoassay using magnetic latex particles and a proprietary 138 
acridinium ester for chemiluminescence detection. The detection reagent is a recombinant sheep 139 
Fab antibody covalently linked to a tri-sulfo propyl acridinium ester (TSPAE)-BSA conjugate. 140 
TSPAE is a new generation of high-yield acridinium esters developed for enhanced 141 
chemiluminescent detection. Simultaneous addition of solid-phase reagent and detection 142 
reagent to the sample forms a classic sandwich immune complex, which is subsequently 143 
washed. Chemiluminescence is initiated and measured. Relative light units are directly 144 
proportional to the cTnI concentration. The time to first result is 18 minutes. The assay meets 145 
the current International Federation of Clinical Chemistry (IFCC) recommendations for hs-cTn 146 
assays.(24,25) 147 
The hs-cTnT-Elecsys assay (Elecsys 2010, Roche Diagnostics) has a 99th percentile 148 
concentration of 14ng/L with a corresponding CV of 10% at 13ng/L.(5) LoB and LoD have 149 
been determined to be 3ng/L and 5ng/L.(5) The hs-cTnI-Architect assay (ARCHITECT STAT 150 
high-sensitivity troponin I, Abbott Laboratories) has a 99th percentile concentration of 26.2ng/L 151 
with a corresponding CV of <5% and a LoD of 1.9ng/L.(26–28) Estimated glomerular filtration 152 
rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease 153 
formula.(29) 154 
 155 
Derivation of the hs-cTnI-Centaur 0/1h-algorithm 156 
The hs-cTnI-Centaur 0/1h-algorithm was developed in a derivation sample of randomly (1:1 157 
fashion) selected patients with available hs-cTnI-Centaur measurements at baseline and after 158 
1h) according to the central adjudication by two independent cardiologists using all clinical 159 
information including cardiac imaging and serial hs-cTnT-Elecsys concentrations (primary 160 
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adjudication). The 0/1h-algorithm incorporates hs-cTnI-Centaur concentrations at presentation 161 
and absolute hs-cTnI-Centaur changes within 1h (hs-cTnI-Centaur1h – hs-cTnI-Centaur0h) as 162 
well as time since chest pain onset in order to reflect the concept of the current hs-cTn 0/1h-163 
algorithms suggested by the ESC(3) (Supplemental Figure 4). Selection of these parameters 164 
was based on the very high diagnostic accuracy of the combination of blood concentrations at 165 
presentation with absolute changes for rule-out and rule-in of AMI.(7,8,11,12,14,15,21,30,31) 166 
Optimal thresholds for rule-out were selected to allow for a minimal sensitivity and negative 167 
predictive value (NPV) of 99% and were independent from the assay package insert specified 168 
thresholds. Optimal thresholds for rule-in were obtained based on a classification and regression 169 
tree (CART) analysis targeting a minimal positive predictive value (PPV) of 70%.(32,33) 170 
Nodes in the CART tree were constrained to have a minimal number of cases of 20 in parent 171 
and child nodes. If a predefined target performance was missed in the derivation sample using 172 
the CART-derived thresholds, thresholds were changed stepwise until the predefined 173 
performance was fulfilled.  174 
 175 
Derivation of the hs-cTnI-Centaur 0/2h-algorithm 176 
The hs-cTnI-Centaur 0/2h-algorithm was developed in a derivation sample randomly (2:1 177 
fashion in order to compensate for the slightly lower number of patients with available 2h versus 178 
1h samples and to ensure a sufficient number of patients in the derivation cohort) selected of 179 
patients with available hs-cTnI-Centaur measurements at ED presentation and after 2h (Online 180 
Supplemental file) according to the central adjudication by two independent cardiologists 181 
using all clinical information including cardiac imaging and serial hs-cTnT-Elecsys 182 
concentrations (primary adjudication).  183 
 184 
Validation of the hs-cTnI-Centaur 0/1h- and 0/2-algorithm 185 
 186 
The algorithms developed in the derivation samples were tested for their diagnostic accuracy 187 
in internal validation samples consisting of the remaining subjects. The optimal decision values 188 
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derived in the derivation sample were rounded to give whole values in ng/L. The first validation 189 
was done according to the central adjudication by two independent cardiologists using all 190 
clinical information including cardiac imaging and serial hs-cTnT-Elecsys concentrations. The 191 
secondary validation was done according to the central adjudication by two independent 192 
cardiologists using all clinical information including cardiac imaging and serial hs-cTnI-193 
Architect concentrations. 194 
 195 
Follow-up and clinical endpoints 196 
Clinical follow-up is described in detail in the Online Supplemental file. The co-primary 197 
prognostic endpoints were overall survival after 30 days and two years. The secondary 198 
prognostic endpoint was major adverse cardiac events (MACE) defined as the composite of all-199 
cause mortality, AMI, cardiogenic shock, ventricular tachyarrhythmias, or higher-degree 200 
atrioventricular block at 30-days. 201 
 202 
Statistical analysis 203 
For the primary analysis, serial hs-cTnT-Elecsys concentrations were used for final 204 
adjudication. For the secondary analysis, serial hs-cTnI-Architect concentrations were used for 205 
final adjudication. Receiver-operating characteristics (ROC) curves were constructed to assess 206 
the sensitivity and specificity throughout the hs-cTn-concentrations to compare the ability to 207 
diagnose AMI. Subgroup analyses were performed in patients presenting to the ED very soon 208 
(≤2h), soon (≤3h) and late (>3h) after chest pain onset/maximum as well as in women and men. 209 
We further included analysis using sex-specific cut-offs and investigated the performance of 210 
the ESC 0/3h-algorithm. Biological equivalent concentrations were determined by plotting log-211 
transformed hs-cTnI-Centaur and hs-cTnI-Architect or hs-cTnT-Elecsys concentrations from 212 
the same sample.(22) The areas under the ROC curves (AUC) were compared as recommended 213 
by DeLong et al.(34) or by z-statistic, as appropriate (Online Supplemental file). 214 
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Safety was assessed as the NPV and the sensitivity for AMI for rule-out, accuracy for 215 
rule-in as the PPV and specificity for AMI, and efficacy was quantified as the percentage of 216 
patients triaged towards rule-out or rule-in for AMI within 1h or 2h. 217 
Statistical analyses were performed using IBM SPSS Statistics for Windows, version 218 
23.0 (SPSS Inc) and MedCalc 17.6 (MedCalc Software). 219 
 220 
 221 
 222 
 223 
 224 
 225 
 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
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Results 241 
Characteristics of patients 242 
From April 2006 to February 2013, 1755 patients eligible for this analysis were enrolled 243 
(Supplemental Figure 1). Thirty-four percent of patients presented to the ED within the first 244 
three hours after chest pain onset. Baseline characteristics of all patients are shown in Table 1 245 
and of patients in the derivation and validation cohorts are shown in Supplemental Table 2.  246 
 247 
Adjudicated final diagnosis 248 
The adjudicated final diagnosis was AMI in 318/1755 patients (18%), unstable angina in 249 
156/1755 (9%), cardiac symptoms of origin other than coronary artery disease such as 250 
tachyarrhythmia, Tako-Tsubo cardiomyopathy, heart failure or myocarditis in 238/1755 (14%), 251 
non-cardiac symptoms in 968/1755 (55%), and unknown in 75/1755 (4%). Final diagnoses 252 
according to the second final adjudication including hs-cTnI (Architect) were similar (Online 253 
Supplemental file).  254 
 255 
Concentrations of hs-cTnI-Centaur at presentation according to final diagnoses 256 
Concentrations of hs-cTnI-Centaur at ED presentation were significantly higher in patients with 257 
AMI as compared to patients with other final diagnoses (P<0.001). Median concentrations of 258 
hs-cTnI-Centaur in patients with AMI were 235ng/L (IQR, 39-1018), with unstable angina 259 
8.5ng/L (IQR, 5.0-17), with cardiac, but not coronary disease 12ng/L (IQR, 4.7-36), with non-260 
cardiac disease 4ng/L (IQR, 2.4-7.6), and with unknown diagnosis 4.2ng/L (IQR, 2.8-7.0; 261 
Figure 1). Similar findings emerged according to the second final adjudicated diagnosis 262 
including hs-cTnI (Architect; Supplemental Figure 2). 263 
 264 
Diagnostic accuracy for AMI 265 
The diagnostic accuracy of measurements obtained at presentation, as quantified by AUCs, for 266 
the hs-cTnI-Centaur assay was 0.94 (95%CI, 0.92-0.96) and comparable to hs-cTnT-Elecsys 267 
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0.95 (95%CI, 0.93-0.97), and hs-cTnI-Architect 0.93 (95%CI, 0.90-0.96), respectively 268 
(P=0.370 and P=0.780 for direct comparisons; Figure 2A). For hs-cTnI-Centaur, the AUCs for 269 
concentrations at 1h, 2h, and 3h were 0.95 (95%CI, 0.93-0.96), 0.95 (95%CI, 0.94-0.97), and 270 
0.97 (95%CI, 0.95-0.99), respectively (Supplemental Table 3A). Similar findings emerged 271 
according to the second final adjudicated diagnosis including hs-cTnI (Architect; 272 
Supplemental Figure 3A). The diagnostic performances of uniform and sex-specific cut-offs 273 
are summarized in Table 2B and detailed information given in the Online Supplemental 274 
Results. 275 
 276 
Subgroup analyses according to time since chest pain onset and sex 277 
Diagnostic accuracy at presentation was also similar in the predefined subgroups (Online 278 
Supplemental Results, Supplemental Table 3B, Figure 2B). Again, similar findings emerged 279 
according to the second final adjudicated diagnosis including hs-cTnI (Architect; 280 
Supplemental Figure 3B). 281 
 282 
Hs-cTnI-Centaur 0/1h-algorithm  283 
The diagnostic performance of the hs-cTnI-Centaur 0/1h-algorithm in the derivation cohort is 284 
shown in Figure 3A, and Supplemental Figure 5A.  285 
 286 
Validation of the hs-cTnI-Centaur 0/1h-algorithm 287 
Applying the derived optimal cut-off levels to the internal validation cohort, 313/675 patients 288 
(46%) could be classified as rule-out with a corresponding NPV of 99.7% (95%CI, 97.8-100) 289 
and a sensitivity of 99.1% (95%CI, 95.3-100; Figure 3B and Supplemental Figure 5B). Direct 290 
rule-out based on a single hs-cTnI-Centaur concentration at presentation was feasible in 291 
111/675 patients (16%). One patient with AMI was missed out of 675 patients with suspected 292 
AMI in the validation sample (Supplemental Table 4 for detailed patient characteristics). The 293 
0/1h-algorithm classified 120/675 patients (18%) as rule-in with a corresponding PPV of 72.5% 294 
(95%CI, 63.6-80.3) and a specificity of 94.1% (95%CI, 91.8-95.9). Direct rule-in based on a 295 
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single hs-cTnI-Centaur concentration at presentation was feasible in 79/675 patients (12%). 296 
Overall, the hs-cTnI-Centaur 0/1h-algorithm allowed a definite diagnosis after 1h in 433/675 297 
patients (64%; either rule-out or rule-in). The remaining 242/675 patients (36%) were classified 298 
to observe with an AMI prevalence of 11% (95%CI, 8-15). Similar findings emerged when 299 
assessing the diagnostic performance of the hs-cTnI-Centaur 0/1h-algorithm in the validation 300 
cohort using the second final adjudication including hs-cTnI (Architect, Supplemental Figure 301 
6). 302 
 303 
Direct comparison of the hs-cTnI-Centaur 0/1h-algorithm with the ESC 0/1h-algorithms 304 
using hs-cTnT-Elecsys and hs-cTnI-Architect  305 
Overall, the diagnostic performance of the hs-cTnI-Centaur 0/1h-algorithm was similar to that 306 
of the hs-cTnT-Elecsys 0/1h-algorithm and the hs-cTnI-Architect 0/1h-algorithm 307 
(Supplemental Figure 7+8).  308 
 309 
Hs-cTnI-Centaur 0/2h-algorithm 310 
Optimal thresholds for rule-out and rule-in are shown in Figure 3C.  311 
 312 
Validation of the hs-cTnI-Centaur 0/2h-algorithm 313 
Applying the derived optimal thresholds to the internal validation cohort, 200/361 patients 314 
(55%) could be classified as rule-out with a corresponding NPV of 100% and a sensitivity of 315 
100% (95%CI, 94.1-100; Figure 3D, Supplemental Figure 9).  316 
 317 
Prognostic performance of the hs-cTnI-Centaur 0/1h-algorithm  318 
Median follow-up time was 772 days (IQR, 734-915) with 13 deaths occurring within 30 days 319 
and 99 deaths within two years. Cumulative 30-days survival rates were 100%, 98.6% and 320 
97.5% (log-rank, P=0.002) in the rule-out, observe and rule-in group, respectively. At 2 years, 321 
cumulative survival rates were 98.4%, 89.2% and 85.1%, respectively (log-rank, P<0.001; 322 
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Figure 4). Similar findings emerged regarding MACE-free survival including the index event 323 
(Supplemental Figure 10).  324 
Biological equivalent concentrations 325 
Biological equivalent concentrations for hs-cTnI-Centaur of hs-cTnI-Architect and hs-cTnT-326 
Elecsys are shown in Supplemental Figure 11. 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
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 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
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Discussion  367 
This large multicenter study was performed to validate the diagnostic performance and clinical 368 
utility of the novel hs-cTnI-Centaur assay for the early diagnosis of AMI. We report nine major 369 
findings:  370 
First, the diagnostic accuracy of hs-cTnI-Centaur was very high for concentrations obtained at 371 
ED presentation as well as 1h- and 2h-changes and their combinations with an AUC ranging 372 
from 0.94 to 0.97. Second, the diagnostic accuracy of hs-cTnI-Centaur was comparable to the 373 
two hs-cTn assays already in clinical use: hs-cTnT-Elecsys and hs-cTnI-Architect. This finding 374 
was consistent in the overall population as well as in early presenters. Third, as compared to 375 
the uniform cut-offs, sex-specific cut-offs provided slightly higher sensitivity and NPV, but 376 
lower specificity and PPV in women, and slightly lower sensitivity and NPV, but higher 377 
specificity and PPV in men. Whereas the use of the sex-specific 99th percentile in women seems 378 
reasonable for classification of women at low risk, the use in men seems to be associated with 379 
potential harm. Fourth, the application of the derived 0/1h-algorithm for hs-cTnI-Centaur, 380 
defined by concentrations at presentation and its absolute change within 1h, in the internal 381 
validation cohort resulted in very high safety in the rule-out zone with a NPV of 99.7% and a 382 
sensitivity of 99.1%, as well as a high PPV in the rule-in zone for AMI. Only two patients were 383 
missed, both with falling hs-cTn concentrations possibly due to late presentation to the ED. 384 
Fifth, overall, the performance of the 0/1h-algorithm for hs-cTnI-Centaur was comparable to 385 
that of the established 0/1h-algorithms for hs-cTnT-Elecsys and hs-cTnI-Architect, and also 386 
similar to their performance in previous studies.(3,7,21) In contrast to the established 0/1h-387 
algorithms, the novel hs-cTnI-Centaur 0/1h-algorithm uses a slightly higher cut-off (3ng/L) for 388 
direct rule-out instead of its LoD (2ng/L). This resulted in a greater proportion of patients ruled-389 
out than using the LoD (16% vs. 7%; P<0.001). As with most other early rule-out algorithms, 390 
the cut-offs for rule-out of AMI of the 0/1h-algorithm and the 0/2h-algorithm for hs-cTnI-391 
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Centaur are very low and therefore in a range where the assay has suboptimal precision. This 392 
aspect highlights the need for further independent validation studies. As it is unknown to what 393 
extent the analytical qualification as a hs-cTnI assay correlate with the diagnostic accuracy for 394 
AMI as quantified by the AUC and the clinical utility as quantified by the performance of the 395 
0/1h- and 0/2h-algorithms, it was mandatory to prospectively evaluate them in this large 396 
diagnostic study. Sixth, the application of the derived 0/2h-algorithm for the hs-cTnI-Centaur, 397 
defined by concentrations at presentation and its absolute change within 2h, in the internal 398 
validation cohort resulted also in a very high NPV and sensitivity of 100%, and high PPV for 399 
AMI. Seventh, the overall efficacy of the novel hs-cTnI-Centaur 0/1h- and 0/2h-algorithms 400 
were high by assigning about 70% of patients to either rule-out or rule-in within 1h or 2h (rule-401 
out efficacy was even higher for the 0/2h-algorithm), with only about 30% of patients remaining 402 
in the observe zone. Of note, more than one fourth (28%) of all patients were either directly 403 
ruled-out or ruled-in for AMI at presentation based on a single hs-cTnI-Centaur concentration 404 
without the need for serial hs-cTnI sampling. Eighth, these findings were internally validated 405 
when using as an additional reference standard the second adjudication including serial hs-cTnI 406 
concentrations. By the use of a reference standard including hs-cTnI in addition to a reference 407 
standard including hs-cTnT, this large diagnostic study of patients presenting with suspected 408 
AMI overcame the small but inherent verification bias of previous studies that used only one 409 
(hs)-cTn assay as part of the reference standard(7,11,19,23,30). Using the second adjudication 410 
resulted in final diagnoses that slightly differed from those using the primary adjudication. This 411 
can be explained by the differences among both assays, e.g. by the fact that 99th percentiles are 412 
not biological equivalent to each other. This methodological detail further increases the 413 
generalizability of our findings.  414 
Ninth, survival in patients assigned to the rule-out zone by the 0/1h-algorithm was 100% after 415 
30 days and 98.4% after two years, further underscoring the safety of early discharge from the 416 
ED for most patients classified as rule-out, with further outpatient management as clinically 417 
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appropriate. Similarly, MACE-free survival within 30 days in patients triaged towards ruled-418 
out was very high at 99.4%. Of note, the rather high rate of all-cause mortality during follow-419 
up and MACE within 30 days of observe patients can be at least in part explained by the high 420 
incidence of chronic diseases such as chronic heart failure which are directly associated with 421 
high rates of both overall mortality and MACE.  422 
The findings of the present study have enormous clinical implications as they will allow a 423 
substantial number of additional institutions to clinically introduce hs-cTn testing into their 424 
management of patients with suspected AMI and, thereby, to adopt current clinical practice 425 
guideline recommendations without the logistic challenges and costs of introducing an 426 
additional analyzer exclusively for the measurement of hs-cTn.(2–4,10) These findings also 427 
extend and corroborate previous work with the two other hs-cTn assays.(3,7,19,30) 428 
Accordingly, the same concept and caveats apply to the most appropriate clinical use of any of 429 
the three hs-cTn assays and their respective 0/1h- and 0/2h-algorithms in the early diagnosis of 430 
AMI.(3,7,11,15,19,30) First, these algorithms should only be applied after STEMI has been 431 
ruled-out by the ECG performed at presentation. Second, although the hs-cTnI-Centaur 0/1h- 432 
and 0/2h-algorithm had a very high NPV and sensitivity for AMI, they should always be used 433 
in conjunction with all other clinical information including a detailed assessment of chest pain 434 
characteristics, physical examination, and the ECG. Additional measurements of hs-cTnI at e.g. 435 
3h are advised whenever the patient remains symptomatic or clinical judgment still argues in 436 
favor of AMI. These will help to detect the rare but existing phenomenon of delayed release of 437 
hs-cTn into the circulation, particularly in early presenters.(3) It will also help detect rare but 438 
possible errors in the handling of the clinical blood samples, e.g. blood sample of a patient 439 
without AMI (and normal hs-cTnI concentrations) erroneously attributed to a patient with AMI. 440 
Third, not all patients triaged towards rule-out of AMI are appropriate candidates for early 441 
discharge from the ED. Fourth, patients triaged towards rule-in in general are candidates for 442 
early coronary angiography. About 75% of patients triaged towards rule-in will be found to 443 
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have AMI. Most of the remaining patients in the rule-in zone will still benefit from coronary 444 
angiography for diagnostic and possible therapeutic purposes as they will be found to have 445 
Tako-Tsubo cardiomyopathy, myocarditis, and unstable angina.(3)  446 
Some limitations merit consideration when interpreting these findings. First, this study 447 
was conducted in ED patients with symptoms suggestive of AMI. Further studies are required 448 
to quantify the utility of rule-out and rule-in strategies in patients with either a higher pre-test 449 
probability (e.g., in a coronary care unit setting) or in patients with a lower pre-test probability 450 
(e.g., in a general practitioner setting) for AMI, as well as in the inherently challenging group 451 
of critically ill patients. Second, the data presented were obtained from a prospective diagnostic 452 
study. Studies applying the diagnostic algorithms prospectively for clinical decision-making 453 
are warranted. Third, not all patients with acute chest pain had a second set of laboratory 454 
measurements at 1h and later. The most common reasons for missing blood samples were 455 
logistic issues in the ED that precluded blood draw around the 1h-window. This limitation is 456 
inherent to studies enrolling consecutive patients and is very unlikely to have affected the main 457 
findings of the present study. Fourth, although we used the most stringent methodology to 458 
adjudicate the presence or absence of AMI including central adjudication by experienced 459 
cardiologists, we still may have misclassified a small number of patients.(4) Fifth, our findings 460 
are specific to the hs-cTnI-Centaur assay. The derived 0/1h- and 0/2h-algorithm cannot be 461 
generalized to other hs-cTnI assays. Sixth, we cannot generalize our findings to patients with 462 
terminal kidney failure requiring dialysis, since they were excluded from this study. Finally, we 463 
acknowledge that using hs-cTnT , an assay that is different from hs-cTnI assays, as the gold 464 
standard assay for the primary validation may not be the ideal way to validate a hs-cTnI assay. 465 
However, we addressed this potential limitation by use of a secondary adjudication including 466 
serial hs-cTnI concentrations. 467 
In conclusion, the diagnostic accuracy of the novel hs-cTnI-Centaur assay for AMI is 468 
very high and comparable to both well-established hs-cTn assays: hs-cTnT-Elecsys and hs-469 
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cTnI-Architect. Simple algorithms incorporating hs-cTnI-Centaur concentrations at 470 
presentation and absolute changes within the first 1h or 2h, allow triage towards safe rule-out 471 
and accurate rule-in of AMI within 1h or 2h in the majority of patients presenting with chest 472 
pain to the ED.  473 
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Numbers are presented as median (IQR) or numbers (%). CPO denotes chest pain onset; AMI 729 
denotes acute myocardial infarction; ECG denotes electrocardiogram; ACEIs denotes 730 
angiotensin-converting-enzyme inhibitors. ARBs denotes angiotensin receptor blockers.  731 
732 
Table 1 Baseline Characteristics of the Patients 
 
All patients 
(n=1755) 
AMI  
(n=318) 
No AMI  
(n=1437) P-Value 
Age – years 62 (49-75) 72 (59-80) 60 (47-73) <0.001 
Male gender – no. (%) 
Time from cpo to first blood draw - hours 
1216 (69) 
5 (3-10) 
231 (73) 
5 (3-11) 
985 (69) 
5 (3-10) 
0.15 
0.41 
Early presenters (within 3h after cpo) 603 (34%) 106 (33%) 497 (35%) 0.67 
Risk factors – no. (%)     
Hypertension 1087 (62) 255 (80) 832 (58) <0.001 
Hypercholesterolemia 876 (50) 219 (69) 657 (46) <0.001 
Diabetes 317 (18) 84 (27) 233 (16) <0.001 
Current smoking 442 (25) 77 (24) 365 (25) 0.69 
History of smoking 658 (38) 131 (42) 527 (37) 0.11 
History – no. (%)     
Coronary artery disease 619 (35) 160 (50) 459 (32) <0.001 
Previous MI 409 (23) 107 (34) 302 (21) <0.001 
Previous revascularization 479 (27) 116 (37) 363 (25) <0.001 
Peripheral artery disease 116 (7) 48 (15) 68 (5) <0.001 
Previous stroke 89 (5) 24 (8) 65 (5) 0.03 
ECG findings – no. (%)     
Left bundle branch block 55 (3) 15 (5) 40 (3) 0.07 
ST-segment depression 156 (9) 88 (28) 68 (5) <0.001 
T-wave inversion 152 (9) 39 (12) 113 (8) 0.01 
No significant ECG abnormalities 1358 (77) 169 (53) 1189 (83) <0.001 
Body mass index (kg/m2) 
Laboratory findings 
27 (24-30) 26 (24-29) 27 (24-30) 0.47 
Creatinine clearance, mL/min/m2 84 (68-100) 72 (54-89) 86 (70-102) <0.001 
Chronic medication – no. (%)     
Aspirin 638 (36) 155 (49) 483 (34) <0.001 
Vitamin K antagonists 143 (8) 31 (10) 112 (8) 0.25 
B-blockers 595 (34) 137 (43) 458 (32) <0.001 
Statins 613 (35) 140 (44) 473 (33) <0.001 
ACEIs/ARBs 656 (37) 167 (53) 489 (34) <0.001 
Calcium antagonists 236 (13) 59 (19) 177 (12) 0.003 
Nitrates 
 
200 (11) 65 (20) 135 (9) <0.001 
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Table 2A 
 
Performance of the hs-cTnI-Centaur 0/1h-algorithm in the validation cohort (n=675) according to time since cpo 
 
Time since cpo 
until first study 
blood draw 
Direct rule-out 
0h<3ng/L (if cpo>3h) 
 
Overall rule-out 
Direct rule-out or 
0h<6ng/L AND 1h-delta 
<3ng/L 
Observe zone Direct rule-in 
0h³120ng/L 
Overall rule-in 
0h³120ng/L OR 
1h-delta ³12ng/L 
£1h  
(n=38/675) n/a 
19/38 (50%) 
Sens.: 100% (61.0-100) 
NPV: 100% (83.2-100) 
11/38 (29%) 
NSTEMI: 27% 
3/38 (8%) 
Spec.: 96.9% (84.3-99.4) 
PPV: 66.7% (20.8-93.9) 
8/38 (21%) 
Spec.: 84.4% (68.2-93.1) 
PPV: 37.5% (13.7-69.4) 
£2h  
(n=171/675) n/a 
79/171 (46%) 
Sens.: 100% (89.6-100) 
NPV: 100% (95.4-100) 
56/171 (33%) 
NSTEMI: 14% 
17/171 (10%) 
Spec.: 97.8% (93.8-99.3) 
PPV: 82.4% (59.0-93.8) 
36/171 (21%) 
Spec.: 92.0% (86.3-95.5) 
PPV: 69.4% (53.1-82.0) 
£3h  
(n=252/675) n/a 
117/252 (46%) 
Sens.: 100% (92.3-100) 
NPV: 100% (96.8-100) 
83/252 (33%) 
NSTEMI: 13% 
28/252 (11%) 
Spec.: 97.1% (93.8-98.7) 
PPV: 78.6% (60.5-89.8) 
52/252 (21%) 
Spec.: 91.7% (87.2-94.8) 
PPV: 67.3% (53.8-78.5) 
£4h  
(n=325/675) 
16/325 (5%) 
Sens.: 100% (93.5-100) 
NPV: 100% (80.6-100) 
151/325 (47%) 
Sens.: 100% (93.5-100) 
NPV: 100% (97.5-100) 
112/352 (34%) 
NSTEMI: 11% 
33/325 (10%) 
Spec.: 97.4% (94.7-98.7) 
PPV: 78.8% (62.2-89.3) 
62/325 (19%) 
Spec.: 93.0% (89.3-95.4) 
PPV: 69.4% (57.0-79.4) 
£5h  
(n=380/675) 
26/380 (7%) 
Sens.: 100% (94.2-100) 
NPV: 100% (87.1-100) 
176/380 (46%) 
Sens.: 100% (94.2-100) 
NPV: 100% (97.9-100) 
134/380 (35%) 
NSTEMI: 10% 
40/380 (11%) 
Spec.: 97.2% (94.7-98.5) 
PPV: 77.5% (62.5-87.7) 
70/380 (19%) 
Spec.: 93.4% (90.1-95.6) 
PPV: 70.0% (58.5-79.5) 
£6h  
(n=427/675) 
37/427 (9%) 
Sens.: 100% (94.8-100) 
NPV: 100% (90.6-100) 
196/427 (46%) 
Sens.: 98.6% (92.3-99.7) 
NPV: 99.5% (97.2-99.9) 
151/427 (35%) 
NSTEMI: 9% 
44/427 (10%) 
Spec.: 97.2% (94.9-98.5) 
PPV: 77.3% (63.0-87.2) 
80/427 (19%) 
Spec.: 93.0% (89.9-95.2) 
PPV: 68.8% (57.9-77.8) 
  
Performance of the hs-cTnI-Centaur 0/2h-algorithm in the validation cohort (n=361) according to time since cpo 
 
Time since cpo 
until first study 
blood draw 
Direct rule-out 
0h<3ng/L (if cpo>3h) 
Overall rule-out 
Direct rule-out or 
0h<8ng/L AND 1h-delta 
<7ng/L 
Observe zone Direct rule-in 
0h³120ng/L 
Overall rule-in 
0h³120ng/L OR 
1h-delta ³20ng/L 
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 733 
 734 
CPO denotes chest pain onset; NPV denotes negative predictive value; PPV denotes positive predictive value. Sens. denotes sensitivity; Spec. 735 
denotes specificity. n/a denotes not available736 
£1h  
(n=24/361) n/a 
16/24 (67%) 
Sens.: 100% (43.9-100) 
NPV: 100% (80.6-100) 
3/24 (12%) 
NSTEMI: 0% 
2/24 (8%) 
Spec.: 100% (84.5-100) 
PPV: 100% (34.2-100) 
5/24 (21%) 
Spec.: 90.5% (71.1-97.3) 
PPV: 60.0% (23.1-88.2) 
£2h  
(n=87/361) n/a 
48/87 (55%) 
Sens.: 100% (79.6-100) 
NPV: 100% (92.6-100) 
23/87 (26%) 
NSTEMI: 9% 
8/87 (9%) 
Spec.: 100% (94.9-100) 
PPV: 100% (67.6-100) 
16/87 (18%) 
Spec.: 95.8% (88.5-98.6) 
PPV: 81.3% (57.0-93.4) 
£3h  
(n=133/361) n/a 
75/133 (56%) 
Sens.: 100% (72.2-100) 
NPV: 100% (95.1-100) 
36/133 (27%) 
NSTEMI: 14% 
13/133 (10%) 
Spec.: 100% (96.6-100) 
PPV: 100% (77.2-100) 
22/133 (17%) 
Spec.: 96.4% (91.0-98.6) 
PPV: 81.8% (61.5-92.7) 
£4h  
(n=175/361) 
11/175 (6%) 
Sens.: 100% (87.9-100) 
NPV: 100% (74.1-100) 
102/175 (58%) 
Sens.: 100% (87.9-100) 
NPV: 100% (96.4-100) 
45/175 (26%) 
NSTEMI: 13% 
17/175 (10%) 
Spec.: 99.3% (96.2-99.9) 
PPV: 94.1% (73.0-99.0) 
28/175 (16%) 
Spec.: 95.9% (91.4-98.1) 
PPV: 78.6% (60.5-89.8) 
£5h  
(n=204/361) 
18/204 (9%) 
Sens.: 100% (89.3-100) 
NPV: 100% (82.4-100) 
115/204 (56%) 
Sens.: 100% (89.3-100) 
NPV: 100% (96.8-100) 
58/204 (28%) 
NSTEMI: 16% 
20/204 (10%) 
Spec.: 98.3% (95.0-99.4) 
PPV: 85.0% (64.0-94.8) 
31/204 (15%) 
Spec.: 95.3% (91.1-97.6) 
PPV: 74.2% (56.8-86.3) 
£6h  
(n=229/361) 
23/229 (10%) 
Sens.: 100% (89.9-100) 
NPV: 100% (85.7-100) 
130/229 (57%) 
Sens.: 100% (89.8-100) 
NPV: 100% (97.1-100) 
64/229 (28%) 
NSTEMI: 14% 
23/229 (10%) 
Spec.: 97.9% (94.8-99.2) 
PPV: 82.6% (62.9-93.0) 
35/229 (15%) 
Spec.: 94.9% (90.8-97.2) 
PPV: 71.4% (54.9-83.7) 
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 737 
 738 
 739 
NPV denotes negative predictive value; PPV denotes positive predictive value; perc. denotes percentile. 740 
Table 2b 
Diagnostic Performance of Uniform and Sex-specific Cut-Offs  
Final Adjudication including hs-cTnT-Elecsys Final Adjudication including hs-cTnI-Architect 
Hs-cTnI-Centaur Sensitivity NPV Specificity PPV Sensitivity NPV Specificity PPV 
Uniform 99th perc 
47ng/L. 
70.4 
(65.2-75.2) 
93.4 
(92.0-94.6) 
93.3 
(91.9-94.5) 
70.0 
(64.8-74.8) 
75.5 
(70.3-80.0) 
94.9 
(93.6-95.9) 
93.5 
(92.1-94.6) 
70.3 
(65.1-75.1) 
Men 99th perc. 
58ng/L 
65.2 
(58.9-71.1) 
92.1 
(90.3-93.6) 
94.6 
(93.0-95.9) 
73.9 
(67.4-79.5) 
70.8 
(64.3-76.5) 
93.9 
(92.2-95.2) 
94.7 
(93.2-95.9) 
73.9 
(67.4-79.5) 
Women 99th perc. 
39ng/L 
77.3 
(67.5-84.8) 
95.4 
(93.0-97.0) 
92.0 
(89.1-94.2) 
65.4 
(55.8-73.8) 
80.2 
(70.6-87.3) 
96.1 
(93.8-97.5) 
92.3 
(89.4-94.4) 
66.3 
(56.8-74.7) 
Hs-cTnI-Architect  
Uniform 99th perc. 
26.2ng/L 
77.7 
(73.3-81.6) 
93.9 
(92.6-95.1) 
92.5 
(91.1-93.8) 
68.4 
(63.3-73.2) 
78.9 
(73.9-83.1) 
95.5 
(94.3-96.5) 
92.9 
(91.4-94.1) 
69.3 
(64.2-74.0) 
Men 99th perc. 
34.2ng/L 
67.0 
(60.6-72.7) 
92.4 
(90.6-93.9) 
94.3 
(92.7-95.6) 
73.3 
(67.0-78.9) 
73.1 
(66.8-78.6) 
94.3 
(92.7-95.6) 
94.5 
(92.9-95.8) 
73.8 
(67.5-79.3) 
Women 99th perc. 
15.6ng/L 
84.1 
(75.0-90.3) 
96.6 
(94.3-97.9) 
87.6 
(84.2-90.3) 
56.9 
(48.3-65.1) 
88.4 
(79.9-93.6) 
97.5 
(95.5-98.7) 
88.1 
(84.7-90.7) 
58.5 
(49.9-66.6) 
Hs-cTnT-Elecsys  
Uniform 99th perc 
14ng/L 
94.3 
(91.2-96.4) 
98.4 
97.5-99.0) 
78.1 
(75.9-80.2) 
48.9 
(44.9-52.8) 
93.3 
(89.9-95.6) 
98.2 
(97.3-98.9) 
76.9 
(74.7-79.0) 
45.3 
(41.4.49.2) 
Men 99th perc. 
15.5ng/L 
91.3 
(87.0-94.3) 
97.5 
(96.2-98.4) 
80.6 
(78.0-83.0) 
52.4 
(47.5-57.2) 
89.6 
(84.8-93.0) 
97.3 
(95.9-98.2) 
79.0 
(76.4-81.4) 
47.4 
(42.5-52.3) 
Women 99th perc. 
9ng/L 
98.9 
(93.8-99.8) 
99.6 
(97.9-99.9) 
58.9 
(54.3-63.3) 
32.0 
(26.7-37.7) 
97.7 
(91.9-99.4) 
99.2 
(97.3-99.8) 
58.4 
(53.8-62.9) 
30.9 
(25.7-36.6) 
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Figure Legends  
 
 
 
Boxes represent medians and interquartile ranges (IQRs), while whiskers display the smallest 
and the largest non-outliers. Rings display outliers further than 1.5 IQRs and boxes display 
outliers further than 3 IQRs from the respective end of the box. AMI denotes acute myocardial 
infarction; hs-cTnI denotes high-sensitivity cardiac troponin I; UA denotes unstable angina.    
 
 
Receiver operating characteristic (ROC) curves describing the diagnostic performance of the 
three high-sensitivity cardiac troponin assays at presentation for the diagnosis of acute 
myocardial infarction. 
 
 
 
 
 
Receiver operating characteristic (ROC) curves describing the diagnostic performance of the 
three high-sensitivity cardiac troponin assays at presentation for the diagnosis of acute 
myocardial infarction in patients presenting to the emergency department within three hours 
after chest pain onset. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Boxplots showing Concentrations of Hs-cTnI-Centaur at Presentation according to the Final Diagnosis  
Figure 2A Diagnostic Accuracy of High-Sensitivity Cardiac Troponin Assays at Presentation for the Diagnosis of Acute Myocardial Infarction 
Figure 2B 
Diagnostic Accuracy of High-Sensitivity Cardiac Troponin Assays at 
Presentation for the Diagnosis of Acute Myocardial Infarction in Early 
Presenters  
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(A) Performance of the hs-cTnI-Centaur 0/1h-algorithm in the derivation cohort and (B) 
validation cohort. │Delta 1h│ denotes absolute (unsigned) change of high-sensitivity cardiac 
troponin I within 1 hour; NSTEMI denotes non-ST-elevation myocardial infarction; NPV 
denotes negative predictive value; Sens. denotes sensitivity; PPV denotes positive predictive 
value; Spec. denotes specificity. *if chest pain onset >3h before presentation to the emergency 
department.  
 
 
 
 
(C) Performance of the hs-cTnI-Centaur 0/2h-algorithm in the derivation cohort and (D) 
validation cohort. │Delta 2h│ denotes absolute (unsigned) change of high-sensitivity cardiac 
troponin I within 2 hours; NSTEMI denotes non-ST-elevation myocardial infarction; NPV 
denotes negative predictive value; Sens. denotes sensitivity; PPV denotes positive predictive 
value; Spec. denotes specificity. *if chest pain onset >3h before presentation to the emergency 
department. 
 
 
 
Kaplan-Meier curves depicting overall survival within 30 days and 720 days according to 
classification of the high-sensitivity cardiac troponin I Centaur 0/1h-algorithm.  
 
 
 
Figure 3 
A+B 
Performance of the High-Sensitivity Cardiac Troponin I Centaur 0/1h-
algorithm in the Derivation and Validation Cohort 
Figure 3 
C+D 
Performance of the High-Sensitivity Cardiac Troponin I Centaur 0/2h-
algorithm in the Derivation and Validation Cohort 
Figure 4 Short-term and Long-term Survival of Patients classified according to the High-sensitivity Cardiac Troponin I Centaur 0/1h-algorithm 
